We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Janssen’s Guselkumab Outperforms Humira in Phase III Psoriasis Trial
Janssen’s Guselkumab Outperforms Humira in Phase III Psoriasis Trial
In a Phase III trial, Janssen’s injectable plaque psoriasis treatment delivered better head-to-head clinical results than international top-selling drug Humira, which amassed over $14 billion in sales in 2015.